Performance of the high-definition circulating tumor cells (HD-CTC) assay in patients with non-small cell lung cancer (NSCLC).

Lyudmila Bazhenova, Jorge J. Nieva, Anand Kolatkar, Madelyn Luttgen, Dena Marinucci, Kelly Bethel, Peter KühnJournal of Clinical Oncology 2012 · DOI

Abstract

e21074 Background: Technologies to isolate and study circulating tumor cells (CTCs) became available in recent years. To date, the most widely employed techniques to detect CTCs use EpCAM based enrichment protocols. However, those assays are only able to find CTCs in a minority of patients with NSCLC, thus limiting its potential applicability. We are reporting performance of a new enrichment-free HD-CTC assay in patients with NSCLC. Methods: This multi-institutional study recruited patients with all stages of NSCLC. Blood was collected at the time of the study entry, 3 weeks, 3m, 6m, 9m, and 12 m. CTCs were identified with enrichment free fluorescent labeling followed by automated digital microscopy. CTCs were physically and morphologically characterized by cytokeratin (CK) intensity, nuclear size, apoptotic changes, and aggregate formation. Cells were classified as HD-CTCs if they met strict morphologic and immunofluorescence characteristics. This assay has been previously validated in 15 normal controls. Results: 106 patients were recruited (I-10, II-3, III-34, IV-59), 78 were chemotherapy naïve. 85%, 79%, and 53% of patients with stages, I+II, III, and IV had detectable HD-CTCs. The chemotherapy naïve cohort had median HD-CTCs of 4.4/mL (range 0–515.6) and a mean of 44.1 (±95.2)/mL. No significant differences were detected in median HD-CTC count between tumor stages (p = 0.32). CK intensity, nuclear size, frequency of apoptosis and aggregate formation was also similar across stages. 28 patients with stage IV disease were analyzed with multiple draws over time. Mean CTC counts were averaged over multiple draws. In each individual patient there was a trend for increased CTC prevalence with advancement of the disease. Median survival was 244 days for patients with ≥5 CTC/mL vs. 304 days for patients with < 5 CTC/mL. HR 4.0, (p=0.0084). Conclusions: The HD-CTC assay can detect CTCs in a high percentage of patients with early and advanced NSCLC. Small subset analysis demonstrated the prognostic value for the enumeration of HD-CTCs. The high prevalence of HD-CTCs across stages could make this assay an ideal candidate for larger scale investigation into prognostic and predictive features of HD-CTCs.
BibTeX
@article{bazhenova2012performance,
  author = {Lyudmila Bazhenova and Jorge J. Nieva and Anand Kolatkar and Madelyn Luttgen and Dena Marinucci and Kelly Bethel and Peter Kühn},
  title = {{Performance of the high-definition circulating tumor cells (HD-CTC) assay in patients with non-small cell lung cancer (NSCLC).}},
  journal = {Journal of Clinical Oncology},
  year = {2012},
  doi = {10.1200/jco.2012.30.15\_suppl.e21074},
}

Loading related content...

Figure